Bridging the gap in the symptomatic heart failure patient journey: insights from the Italian scenario

References

• Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356. doi: 10.1002/ejhf.1858
   PubMed Web of Science ®Google Scholar
• Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128(10):1421–1434. doi: 10.1161/CIRCRESAHA.121.318172
   PubMed Web of Science ®Google Scholar
• Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2014;11(4):354–365. doi: 10.1007/s11897-014-0223-7
   PubMedGoogle Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018;6(8):678–685. doi: 10.1016/j.jchf.2018.03.006
   PubMed Web of Science ®Google Scholar
• Freedland KE, Rich MW, Carney RM. Improving quality of life in heart failure. Curr Cardiol Rep. 2021;23(11):159. doi: 10.1007/s11886-021-01588-y
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. NEJMoa2206286. doi: 10.1056/NEJMoa2206286
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Freemantle N, Tharmanathan P, Calvert MJ, et al. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction - a systematic review and meta-analysis. Eur J Heart Fail. 2006;8(4):433–440. doi: 10.1016/j.ejheart.2005.11.014
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–1338. doi: 10.1056/NEJMoa0906431
   PubMed Web of Science ®Google Scholar
• Lund LH, Jurga J, Edner M, et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J. 2013;34(7):529–539. doi: 10.1093/eurheartj/ehs305
   PubMed Web of Science ®Google Scholar
• Daubert C, Behar N, Martins RP, et al. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2016;ehw270.
   Web of Science ®Google Scholar
• Bressi E, Grieco D, Luermans J, et al. Conduction system pacing for cardiac resynchronization therapy: state of the art, current controversies, and future perspectives. Front Physiol. 2023;14:1124195. doi: 10.3389/fphys.2023.1124195
   PubMed Web of Science ®Google Scholar
• Sharma PS, Naperkowski A, Bauch TD, et al. Permanent His bundle pacing for cardiac resynchronization therapy in patients with heart failure and right bundle branch block. Circ Arrhythm Electrophysiol. 2018 [cited 2022 Jan 9];11(9). doi: 10.1161/CIRCEP.118.006613.
   PubMed Web of Science ®Google Scholar
• Zweerink A, Zubarev S, Bakelants E, et al. His-optimized cardiac resynchronization therapy with ventricular fusion pacing for electrical resynchronization in heart failure. JACC Clin Electrophysiol. 2021;7(7):881–892. doi: 10.1016/j.jacep.2020.11.029
   PubMedGoogle Scholar
• Jastrzębski M, Moskal P, Huybrechts W, et al. Left bundle branch–optimized cardiac resynchronization therapy (LOT-CRT): results from an international LBBAP collaborative study group. Heart Rhythm. 2022;19(1):13–21. doi: 10.1016/j.hrthm.2021.07.057
   PubMed Web of Science ®Google Scholar
• Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42:3427–3520. doi: 10.1093/eurheartj/ehab364
   PubMed Web of Science ®Google Scholar
• Biffi M, Aspromonte N, Bongiorni MG, et al. Modulazione della contrattilità cardiaca nello scompenso cardiaco a frazione di eiezione ridotta: revisione critica delle evidenze ed aspetti decisionali pratici. G Ital Cardiol. 2021;22:15.
   Google Scholar
• Giallauria F, Parlato A, Di Lorenzo A, et al. Cardiac contractility modulation in patients with heart failure with reduced left ventricular ejection fraction. Hearts. 2021;2(1):156–169. doi: 10.3390/hearts2010013
   Google Scholar
• Mohri S, Shimizu J, Mika Y, et al. Electric currents applied during refractory period enhance contractility and systolic calcium in the ferret heart. Am J Physiol Heart Circ Physiol. 2003;284:H1119–1123. doi: 10.1152/ajpheart.00378.2002
   PubMed Web of Science ®Google Scholar
• Lyon AR, Samara MA, Feldman DS. Cardiac contractility modulation therapy in advanced systolic heart failure. Nat Rev Cardiol. 2013;10(10):584–598. doi: 10.1038/nrcardio.2013.114
   PubMed Web of Science ®Google Scholar
• Tschöpe C, Kherad B, Klein O, et al. Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. Eur J Heart Fail. 2019;21(1):14–22. doi: 10.1002/ejhf.1349
   PubMed Web of Science ®Google Scholar
• Kuschyk J, Kloppe A, Schmidt-Schweda S, et al. Cardiac contractility modulation: a technical guide for device implantation. Rev Cardiovasc Med. 2017;18(1):1–13. doi: 10.3909/ricm0825
   PubMed Web of Science ®Google Scholar
• Kuschyk J, Falk P, Demming T, et al. Long‐term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system. Eur J Heart Fail. 2021;23:1160–1169. doi: 10.1002/ejhf.2202
   PubMed Web of Science ®Google Scholar
• Neelagaru SB, Sanchez JE, Lau SK, et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm. 2006;3(10):1140–1147. doi: 10.1016/j.hrthm.2006.06.031
   PubMed Web of Science ®Google Scholar
• Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29:1019–1028. doi: 10.1093/eurheartj/ehn020
   PubMed Web of Science ®Google Scholar
• Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161(2):329–337.e2. doi: 10.1016/j.ahj.2010.10.025
   PubMed Web of Science ®Google Scholar
• Abraham WT, Lindenfeld J, Reddy VY, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design. J Card Fail. 2015;21:16–23. doi: 10.1016/j.cardfail.2014.09.011
   PubMed Web of Science ®Google Scholar
• Abraham WT, Kuck K-H, Goldsmith RL, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. JACC Heart Fail. 2018;6(10):874–883. doi: 10.1016/j.jchf.2018.04.010
   PubMed Web of Science ®Google Scholar
• Wiegn P, Chan R, Jost C, et al. Safety, performance, and efficacy of cardiac contractility modulation delivered by the 2-lead optimizer smart system: the FIX-HF-5C2 study. Circ Heart Fail. 2020;13(4):e006512. doi: 10.1161/CIRCHEARTFAILURE.119.006512
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79:e263–e421. doi: 10.1016/j.jacc.2021.12.012
   PubMed Web of Science ®Google Scholar
• Matta M, Devecchi C, Troccoli R, et al. Cardiac contractility modulation (CCM) Italian registry: preliminary analysis. EP Eur. 2022;24(Supplement_1):euac053.517. doi: 10.1093/europace/euac053.517
   Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Hofer F, Kazem N, Richter B, et al. Prescription patterns of sodium-glucose cotransporter 2 inhibitors and Cardiovascular outcomes in patients with diabetes mellitus and heart failure. Cardiovasc Drugs Ther. 2022;36(3):497–504. doi: 10.1007/s10557-021-07234-7
   PubMed Web of Science ®Google Scholar
• Nota 100 [Internet]. [cited 2022 Oct 2]. Available from: https://aifa.gov.it/nota-100.
   Google Scholar
• Varshney AS, DeFilippis EM, Cowger JA, et al. Trends and outcomes of left ventricular Assist device therapy: JACC focus seminar. J Am Coll Cardiol. 2022;79(11):1092–1107. doi: 10.1016/j.jacc.2022.01.017
   PubMed Web of Science ®Google Scholar
• Adamson RM, Stahovich M, Chillcott S, et al. Clinical strategies and outcomes in advanced heart failure patients older than 70 years of age receiving the HeartMate II left ventricular assist device: a community hospital experience. J Am Coll Cardiol. 2011;57(25):2487–2495. doi: 10.1016/j.jacc.2011.01.043
   PubMed Web of Science ®Google Scholar
• Emerson D, Chikwe J, Catarino P, et al. Contemporary left ventricular Assist device outcomes in an aging population: an STS INTERMACS analysis. J Am Coll Cardiol. 2021;78(9):883–894. doi: 10.1016/j.jacc.2021.06.035
   PubMed Web of Science ®Google Scholar
• Pagani FD. Is durable left ventricular Assist device therapy a viable option for the elderly? J Am Coll Cardiol. 2021;78(9):895–897. doi: 10.1016/j.jacc.2021.07.001
   PubMed Web of Science ®Google Scholar
• Liu E, Lampert BC. Heart failure in older adults: medical management and advanced therapies. Geriatrics. 2022;7(2):36. doi: 10.3390/geriatrics7020036
   PubMed Web of Science ®Google Scholar
• Kraai IH, Vermeulen KM, Luttik MLA, et al. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail. 2013;15(10):1113–1121. doi: 10.1093/eurjhf/hft071
   PubMed Web of Science ®Google Scholar
• Moradi M, Daneshi F, Behzadmehr R, et al. Quality of life of chronic heart failure patients: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(6):993–1006. doi: 10.1007/s10741-019-09890-2
   PubMed Web of Science ®Google Scholar
• Martens P, Verbrugge FH, Nijst P, et al. Mode of death in octogenarians treated with cardiac resynchronization therapy. J Card Fail. 2016;22(12):970–977. doi: 10.1016/j.cardfail.2016.09.023
   PubMed Web of Science ®Google Scholar
• Laish-Farkash A, Bruoha S, Katz A, et al. Morbidity and mortality with cardiac resynchronization therapy with pacing vs. With defibrillation in octogenarian patients in a real-world setting. Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2017;19:1357–1363. doi: 10.1093/europace/euw238
   Google Scholar
• Barra S, Providência R, Paiva L, et al. Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2015;17(2):174–186. doi: 10.1093/europace/euu296
   Google Scholar
• Anker SD, Borggrefe M, Neuser H, et al. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. Eur J Heart Fail. 2019;21(9):1103–1113. doi: 10.1002/ejhf.1374
   PubMed Web of Science ®Google Scholar
• Kloppe A, Lawo T, Mijic D, et al. Long-term survival with cardiac contractility modulation in patients with NYHA II or III symptoms and normal QRS duration. Int J Cardiol. 2016;209:291–295. doi: 10.1016/j.ijcard.2016.02.001
   PubMed Web of Science ®Google Scholar
• Impulse Dynamics. Assessment of implantable CCM in the heart failure group with higher ejection fraction [Internet]. clinicaltrials.gov. Report No.: NCT05064709.; 2022 [cited 2022 Sep 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT05064709
   Google Scholar
• Rao IV, Burkhoff D. Cardiac contractility modulation for the treatment of moderate to severe HF. Expert Rev Med Devices. 2021;18:15–21. doi: 10.1080/17434440.2020.1853525
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Borer JS. Should we revise our approach to ‘optimal medical therapy’? The case of chronic heart failure. Eur Heart J. 2013;34(36):2792–2794. doi: 10.1093/eurheartj/eht279
   PubMed Web of Science ®Google Scholar
• DeFilippis EM, Fiuzat M. Putting the “optimal” in optimal medical therapy. JACC Heart Fail. 2021;9(1):39–41. doi: 10.1016/j.jchf.2020.08.016
   PubMed Web of Science ®Google Scholar
• Masarone D, Rao I, Pacileo G. HOPE for a better selection of patients for cardiac contractility modulation. Expert Rev Med Devices. 2023;20(7):525–528. doi: 10.1080/17434440.2023.2217329
   PubMed Web of Science ®Google Scholar
• Tint D, Florea R, Micu S. New generation cardiac contractility modulation device—filling the gap in heart failure treatment. J Clin Med. 2019;8(5):588. doi: 10.3390/jcm8050588
   PubMed Web of Science ®Google Scholar
• Nägele H, Behrens S, Eisermann C. Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2008;10(12):1375–1380. doi: 10.1093/europace/eun257
   Google Scholar
• Kuschyk J, Nägele H, Heinz-Kuck K, et al. Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT). Int J Cardiol. 2019;277:173–177. doi: 10.1016/j.ijcard.2018.10.086
   PubMed Web of Science ®Google Scholar
• Marchese P, Gennaro F, Mazzotta G, et al. Cardiac contractility modulation therapy in patients with amyloid cardiomyopathy and heart failure, case report, review of the biophysics of CCM function, and AMY-CCM registry presentation. J Clin Med. 2023;12(3):1184. doi: 10.3390/jcm12031184
   PubMed Web of Science ®Google Scholar
• Fastner C, Yuecel G, Hetjens S, et al. Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study. Clin Res Cardiol. 2022;111(11):1286–1294. doi: 10.1007/s00392-022-02089-w
   PubMed Web of Science ®Google Scholar